Clomiphene citrate challenge test and serum anti-Müllerian hormone levels in women with menstrual irregularities and/or infertility by Milewicz, Tomasz et al.
Introduction
Ovarian reserve comprises two elements: the size of
the stock of primordial follicles and the quality of the
oocytes [1]. Ovarian reserve may be assessed by static
tests such as: measure of early follicular phase basal
FSH, inhibin B, morphometric ultrasonographic meas-
ures such as antral follicle count or ovarian volume
[2]. Dynamic tests of ovarian reserve include
clomiphene citrate challenge test (CCCT) and the
GnRH agonist stimulation test [2]. Eldar-Geva et al.
found that dynamic endocrine tests were better than
basal evaluation of FSH, inhibin B or estradiol in pre-
dicting ovarian reserve [2]. Kahraman et al. showed that
abnormal CCCT result is a good predictor of diminished
ovarian reserve and this dynamic test is better than such
static test as basal FSH concentration on day 3. It pro-
vides valuable information for both patients as to their
chances of achieving a pregnancy and also for the med-
ical team deciding on options for stimulation protocols
[3]. Csemiczky et al. found that predictive value of the
CCCT for a negative outcome of IVF treatment was
strong and recommended performing the test before
infertility treatment [4]. Van Swieten EC et al. suggest-
ed that CCCT was a good predictor of IVF and
IVF/ICSI outcome [5]. Women with an abnormal CCT
needed more days of stimulation and higher doses of
gonadotropins to reach an adequate stimulation than
women with a normal CCCT [5].
FOLIA HISTOCHEMICA
ET CYTOBIOLOGICA
Vol. 45, Supp. 1, 2007
pp. 119-121
Clomiphene citrate challenge test and serum 
anti-Müllerian hormone levels in women 
with menstrual irregularities and/or infertility
Tomasz Milewicz1, Józef Krzysiek1, Barbara Błąkała1, 
Magdalena Krzyczkowska-Sendrakowska1, Stanisław Radowicki2, Olga Kacalska1, 
Marta Żabińska1
1Departament of Gynecological Endocrinology, Collegium Medicum, Jagiellonian University, Kraków, 
Poland
2Department of Gynecological Endocrinology Medical Academy Warsaw, Poland
Abstract: Aim: Evaluation of CCCT results and anti-Müllerian hormone (AMH) plasma levels in women with menstrual
cycle irregularities and/or infertility. Patients and methods: 70 patients with menstrual cycle disturbances were recruited to
the study. Clomiphene citrate challenge test (CCCT) was carried out in each patient enrolled. At day 3 of the cycle plasma
basic levels of FSH, estradiol, progesterone, IGFBP-1, TSH, prolactin, DHEAS and anti-Müllerian hormone were measured.
At day 10 of the cycle plasma levels of FSH and estradiol were evaluated. Plasma levels of hormones were measured by
commercially available ELISA kits. Results: 50 women with normal result of CCCT (group A) had higher mean plasma
level of AMH compared to 20 women with abnormal result of CCCT (group B). Mean plasma FSH level at day 3 of the
cycle was lower in group A compared to group B. There were no other statistically significant differences in mean values
of assessed parameters between groups A and B. Taking into account all patients enrolled to the study AMH correlated sig-
nificantly with patients' age and plasma levels of FSH at day 3 and day 10 of the cycle). Basic AMH plasma levels in group
A correlated negatively with plasma levels of FSH at day 3 and day 10. In group B plasma levels of FSH at day 10 of the
cycle also correlated with basic AMH plasma levels. Plasma levels of estradiol at day 10 of the cycle were related inverse-
ly with basic AMH plasma levels in group A, but directly in group B. Conclusion: It should be recommended to perform the
CCCT before infertility treatment. Evaluation of the anti-Müllerian hormone plasma level reflects the results of the CCCT.
Key words: Clomiphene citrate - Challenge test - Anti-Müllerian hormone - Women - Menstrual irregularities - Infertility
Correspondence: T. Milewicz, Dept. of Gynecological
Endocrinology, Collegium Medicum, Jagiellonian University, 
23 Kopernika Str., 31-501 Kraków, Poland; 
e-mail: milewicz@interia.eu
The dimeric glycoprotein anti-Müllerian hormone
(AMH) is a member of the transforming growth factor-β
(TGF-β) family. It was identified as a factor produced
by Sertoli cells, which causes regression of the Mül-
lerian ducts during male fetal development [6].
Expression of AMH mRNA was also found in the
human granulosa cells of the primordial follicles
immediately after their formation and subsequently in
granulose cells of secondary preantral stage follicles
and small antral follicles [7]. AMH protein expression
is detected in the granulose cells up to the moment
when the follicles gain FSH dependence [8]. Durlinger
et al. suggested that AMH might be involved in the
recruitment of FSH sensitive follicles in the early
antral stage [9]. AMH is detected in measurable
amounts in human female serum during reproductive
life span [10]. AMH is associated with ovarian
response in IVF patients with normal FSH levels [11].
Therefore it seemed interesting to evaluate the plas-
ma levels of AMH levels in women menstrual cycle
irregularities with normal and abnormal results of
CCCT test.
Materials and methods
Patients. 70 patients with menstrual cycle disturbances were
recruited to the study. The study was approved by the Jagiellonian
University Bioethical Committee. The clinical characteristics of
the group are shown in Table 1. Each patient had the basal hor-
monal evaluation (FSH, estradiol, TSH, prolactin, DHEAS, prog-
esterone, IGFBP-1) carried out at day 3 of the cycle.
Clomiphene citrate challenge test. Clomiphene citrate challenge
test (CCCT) was carried out in each patient enrolled. At day 3 of
the cycle plasma basic levels of FSH, estradiol, progesterone, TSH,
prolactin, DHEAS, IGFBP-1 and anti-Müllerian hormone were
measured. At day 10 of the cycle plasma levels of FSH and estra-
diol were evaluated. CCCT consisted of 5 days of clomiphene cit-
rate oral administration by 100 mg daily starting from day 3 of the
cycle. All sample tubes were kept and transported in the ice box,
than centrifuged as soon as possible at 4°C (refrigerated centrifuge,
Heraeus, Germany). Plasma was stored frozen at -70°C until the
determination of the hormones, not later then after 3 months of
storage. Frozen samples were thawed slowly only once and incu-
bated for 30 minutes at 4°C prior the analysis. FSH and estradiol
levels were measured using ECLIA Roche kits (sensitivity: 1 ng/ml
for estradiol, cross reaction with LH, TSH, human chorionic
gonadotropin 0.039%; sensitity for FSH of 0.5 mIU/ml less than
5% interference with bilirubin and haemoglobin, cross-reaction
with hCG 0.016%). IGFBP-1 level was measured by ELISA (Diag-
nostic System Laboratories, USA - DSL-10-7800 Active): sensi-
tivity 0.25 ng/ml; the inter- and intra-assay coefficients of variation
were 7.6% and 4.6%, respectively; no cross reactivity with IGF-I,
IGF-II, insulin, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-4, IGFBP-
5, IGFBP-6. Anti-Müllerian hormone levels were measured by
ELISA (Diagnostic System Laboratories, USA - DSL-10-14400
Active). Sensitivity 0.006 ng/ml; the inter- and intra-assay coeffi-
cients of variation were 8.0% and 4.6%, respectively. PRL, TSH,
Testosterone, DHEAS, progesterone were measured by ECLIA
Roche kits. 
Statistical analysis. Descriptive statistics, including mean values,
median and SE, were calculated for all the variables. The data
obtained for women in each group were compared by the paired t-
test. For comparisons between the groups, a non-parametric test
was applied. Significance level was set at p<0.05. Statistical cal-
culations were performed using Statistica 3.1 software.
Results
50 women with normal result of CCCT (group A) had
higher mean plasma level of AMH compared to 20
women with abnormal result of CCCT (group B)
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Table 1. The clinical characteristics of the study group. Table 2. The comparison of clinical characteristics and hormonal
results between group A (patients with normal CCCT result) and
group B (patients with abnormal CCCT result).
(6.95±7.8 μg/l vs 1.45±1.5 μg/l p<0.02). Mean plasma
FSH level at day 3 of the cycle was lower in group A
compared to group B (7.0±1.4 IU/l vs 13.2±5.5 IU/l;
p<0.05). There were no other statistically significant
differences in mean values of assessed parameters
between groups A and B (Table 2). 
Taking into account all patients enrolled to the
study AMH correlated significantly with patients' age
(r=-0.41; p<0.05) and plasma levels of FSH at day 3
and day 10 of the cycle (r=-0.34; p<0.05; r=-0.35;
p<0.05 resp.). Basic AMH plasma levels in group A
correlated negatively with plasma levels of FSH at day
3 and day 10 (r=-0.40; p<0.05; r=-0.35; p<0.05 resp.).
In group B plasma levels of FSH at day 10 of the cycle
also correlated with basic AMH plasma levels (r=-
0.56; p<0.05). Plasma levels of estradiol at day 10 of
the cycle were related inversely with basic AMH plas-
ma levels in group A (r=-0.40; p<0.05), but directly in
group B (r=0.64; p<0.05).
Discussion
Our results indirectly showed that basic plasma levels
of anti-Müllerian hormone measured at day 3 of the
cycle may by applied as one of markers of ovarian
reserve. We showed that women with diminished ovar-
ian reserve (abnormal CCCT result, higher FSH plas-
ma level) had also lower, basic plasma level of AMH
despite the lack of differences in mean age. Te Vet et
al. showed the age related decline of AMH plasma
level [1]. AMH is solely produced by the granulosa
cells of growing follicles and therefore reflects the
quantity and quality of ovarian follicle pool [1]. Rooij
et al. showed the correlation between the plasma lev-
els of AMH and the number of antral follicles and the
number of oocytes retrieved [12]. Eldar-Geva et al.
suggested that basic follicular plasma level of AMH is
the only predictor for achieving pregnancy in IVF
stimulated cycles [1]. 
We also showed that women with abnormal CCCT
result had higher FSH plasma levels during the CCCT
(day 3 and day 10). Csemiczky et al. showed similar
data regarding the link between abnormal results of
CCCT and plasma FSH level [4]. 
Fried et al. found that IGF-I/IGFBP-1 ratio might
have reflected oocyte quality. IGF-I/IGFBP-1 ratio in
serum as well as in follicular fluid was significantly
higher in women who became pregnant [13]. In our
study we observed a tendency toward lower IGFBP-1
serum concentration in women with normal CCCT.
That may correspond to the higher IGF/IGFBP-1 ratio
observed by Fried et al. To conclude, it should be rec-
ommended to perform the CCCT before infertility
treatment. Evaluation of the anti-Müllerian hormone
plasma level reflects the results of the CCCT.
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